2m 2m 2m 2m 2m 2m 2m
- $21.5MMarket Cap
- -86.76%1-Year Change
- Drug Manufacturers - GeneralIndustry
MEDICUS PHARMA (MDCX)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 15
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Medicus Pharma is developing innovative treatments for prostate and skin cancers, including a dissolvable microneedle patch for basal cell carcinoma and a next-generation hormone deprivation therapy with reduced cardiovascular risks.
11/24/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Key Executives
- Faisal Mehmud
- Edward J. Brennan Jr.
- Raza Bokhari
- Viktoria Slepeniuk
- Maryann Adesso
Current Ownership Distribution
- Other12.8M (57.87%)
- Insiders6.9M (31.43%)
- Institutions2.3M (10.52%)
- Mutual Funds37,523 (0.17%)